IMVOKAMAB
Phase 2Monoclonal antibody
RegeneronIMVOKAMAB is one of 81 therapeutic programs targeting Pancreatic Carcinoma. It is currently in Phase 2.
3
Indications
0
Total Trials
0
Active Trials
80
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
69 competitors in Ovarian Carcinoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Avastin
BBio-Thera Solutions
Phase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
Taxol
TevaPhase 2
Nolvadex
AstraZenecaPhase 2
Veliparib
AbbViePhase 3
Stivarga
BayerPhase 2
Eloxatin
TevaPhase 2
Lynparza
AstraZenecaPhase 2
Caelyx
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for IMVOKAMAB. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody
- Highest Phase
- Phase 2
- Company